These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Molecular biology of vaccinia virus and development of a new type of vaccine]. Shida H Uirusu; 1986 Jun; 36(1):23-33. PubMed ID: 3535240 [No Abstract] [Full Text] [Related]
23. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine]. Volz A; Fux R; Langenmayer MC; Sutter G Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):464-72. PubMed ID: 26697713 [TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812 [TBL] [Abstract][Full Text] [Related]
25. [New technology of vaccine production--international prospect of the development. Method and theory of production of vaccines by genetic engineering. a. Vaccinia vector vaccine]. Hashizume S; Morita M; Takahashi F Nihon Rinsho; 1987 Oct; 45(10):2333-41. PubMed ID: 3482288 [No Abstract] [Full Text] [Related]
26. Vaccinia virus: a tool for research and vaccine development. Moss B Science; 1991 Jun; 252(5013):1662-7. PubMed ID: 2047875 [TBL] [Abstract][Full Text] [Related]
27. Safe and effective poxvirus vectors--NYVAC and ALVAC. Paoletti E; Tartaglia J; Taylor J Dev Biol Stand; 1994; 82():65-9. PubMed ID: 7958484 [TBL] [Abstract][Full Text] [Related]
35. The poxvirus A35 protein is an immunoregulator. Rehm KE; Jones GJ; Tripp AA; Metcalf MW; Roper RL J Virol; 2010 Jan; 84(1):418-25. PubMed ID: 19828608 [TBL] [Abstract][Full Text] [Related]
36. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Taylor J; Weinberg R; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E Virology; 1992 Mar; 187(1):321-8. PubMed ID: 1736535 [TBL] [Abstract][Full Text] [Related]
37. Poxvirus Safety Analysis in the Pregnant Mouse Model, Vaccinia, and Raccoonpox Viruses. Roper RL Methods Mol Biol; 2017; 1581():121-129. PubMed ID: 28374246 [TBL] [Abstract][Full Text] [Related]
38. Applications of pox virus vectors to vaccination: an update. Paoletti E Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11349-53. PubMed ID: 8876138 [TBL] [Abstract][Full Text] [Related]
39. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. Santra S; Sun Y; Parvani JG; Philippon V; Wyand MS; Manson K; Gomez-Yafal A; Mazzara G; Panicali D; Markham PD; Montefiori DC; Letvin NL J Virol; 2007 Aug; 81(16):8563-70. PubMed ID: 17553898 [TBL] [Abstract][Full Text] [Related]
40. New approaches to the development of virus vaccines for veterinary use. Yamanouchi K; Barrett T; Kai C Rev Sci Tech; 1998 Dec; 17(3):641-53. PubMed ID: 9850535 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]